Acute myelogenous leukemia in older adults

Oncologist

Volumn 14, Issue 3, 2009, Pages 222-232

  Klepin, Heidi D ^a   Balducci, Lodovico ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Acute myelogenous leukemia; Elderly; Geriatric assessment; Treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; ANTHRACYCLINE; AZACITIDINE; CLOFARABINE; CLORETAZINE; CYTARABINE; DAUNORUBICIN; DEPSIPEPTIDE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; LESTAURTINIB; MITOXANTRONE; NUCLEOSIDE ANALOG; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIOGUANINE; TIPIFARNIB; VALSPODAR; VINCRISTINE; ZORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALGORITHM; ARTICLE; CANCER INCIDENCE; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL DECISION MAKING; COGNITION; COMORBIDITY; DISEASE FREE SURVIVAL; GERIATRIC CARE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT PLANNING;

AGE FACTORS; AGED; ALGORITHMS; GERIATRICS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 64049092296     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0224     Document Type: Article

References (72)

1. National Cancer Institute. Surveillance, Epidemiology, and End Results. SEER Cancer Statistics Review 1975-2005. Available at http://seer.cancer.gov/ csr/1975-2005/index.html, accessed February 25, 2009.
2. Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
3. Büchner T, Berdel WE, Wörmann B et al. Treatment of older patients with AML. Crit Rev Oncol Hematol 2005;56:247-259.
4. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25:1908-1915.
5. Kantarjian H, O'Brien S, Cortes J et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 2006;106:1090-1098.
6. Mori M, Ohta M, Miyata A et al. Treatment of acute myeloid leukemia patients aged more than 75 years: Results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Leuk Lymphoma 2006;47:2062-2069.
7. Vey N, Coso D, Bardou VJ et al. The benefit of induction chemotherapy in patients age ≥75 years. Cancer 2004;101:325-331.
8. Löwenberg B, Zittoun R, Kerkhofs H et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: Arandomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268-1274.
9. Farag SS, Archer KJ, Mrozek K et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 2006;108:63-73.
10. Frohling S, Schlenk RF, Kayser S et al. Cytogenetics and age are major determinants ofoutcome in intensively treated acute myeloid leukemia patients olderthan60years: ResultsfromAMLSGtrialAMLHD98-B. Blood 2006;108:3280-3288.
11. Godwin JE, Smith SE. Acute myeloid leukemia in the older patient. Crit Rev Oncol Hematol 2003;48(suppl):S17-S26.
12. Grimwade D, Walker H, Harrison G et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical ResearchCouncil AML11 trial. Blood 2001;98:1312-1320.
13. Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89:3323-3329.
14. Etienne A, Esterni B, Charbonnier A et al. Comorbidity is an independent predictor ofcomplete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007;109:1376 -1383.
15. Wedding U, Röhrig B, Klippstein A et al. Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 2006;132:665-671.
16. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
17. Bennett JM, Young ML, Andersen JW et al. Long-term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group experience. Cancer 1997;80(11 suppl):2205-2209.
18. Rowe JM, Neuberg D, Friedenberg W et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: A trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-485.
19. Menzin J, Lang K, Earle CC et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162:1597-1603.
20. Lang K, Earle CC, Foster T et al. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 2005;22:943-955.
21. van der Holt B, Breems DA, Berna Beverloo H et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: Results from a prospective clinical trial. Br J Haematol 2007;136:96-105.
22. Gupta V, Chun K, Yi QL et al. Disease biology rather than age is the most important determinant of survival of patients ≥60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005;103:2082-2090.
23. Dohner K, Schlenk RF, Habdank M et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 2005;106:3740-3746.
24. Falini B, Mecucci C, Tiacci E et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-266.
25. Frohling S, Schlenk RF, Breitruck J et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 2002;100:4372-4380.
26. Beran M, Luthra R, Kantarjian H et al. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res 2004;28:547-550.
27. Scholl S, Theuer C, Scheble V et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol 2008;80:208-215.
28. Stirewalt DL, Kopecky KJ, Meshinchi S et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001;97:3589-3595.
29. Buchner T, Berdel WE, Haferlach C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group. J ClinOncol 2009;27:61-69.
30. O'Donnell MR, Appelbaum FR, Baer MR et al. Acute myeloid leukemia clinical practice guidelines inoncology. J Natl ComprCanc Netw 2006;4:16-36.
31. Rees JK, Gray RG, Wheatley K. Dose intensification in acute myeloid leukaemia: Greater effectiveness at lower cost. Principal report ofthe Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party. Br J Haematol 1996;94:89-98.
32. Tilly H, Castaigne S, Bordessoule D et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990;8:272-279.
33. Goldstone AH, Burnett AK, Wheatley K et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302-1311.
34. Löwenberg B, Suciu S, Archimbaud E et al.Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors inacute myeloid leukemia in the elderly: Final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J ClinOncol 1998;16:872-881.
35. Bishop JF, Lowenthal RM, Joshua D et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990;75:27-32.
36. Stone RM, Berg DT, George SL et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995;332:1671-1677.
37. Uyl-de Groot CA, Lowenberg B, Vellenga E et al. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol 1998;100:629-636.
38. Löwenberg B, Suciu S, Archimbaud E et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study ofthe Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997;90:2952-2961.
39. Baer MR, George SL, Dodge RK et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-1232.
40. van der Holt B, Löwenberg B, Burnett AK et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005;106:2646-2654.
41. British Committee for Standards in Haematology; Milligan DW, Grim-wade D, Cullis JO et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006;135:450-474.
42. Stone RM, Berg DT, George SL et al. Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytara-bine. Blood 2001;98:548 -553.
43. Cahn JY, Labopin M, Mandelli F et al. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: A retrospective analysis of the European Bone Marrow Transplant Group. Blood 1995;85:575-579.
44. Gorin NC, Labopin M, Pichard P et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: Importance of the source of stem cells. Br J Haematol 2000;110:887-893.
45. Wallen H, Gooley TA, Deeg HJ et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23:3439-3446.
46. Center for International Blood and Marrow Transplant Research (CIBMTR). Available at http://www.cibmtr.org, accessed August 1, 2008.
47. Estey E, de Lima M, Tibes R et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007;109:1395-1400.
48. Hegenbart U, Niederwieser D, Sandmaier BM et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006;24:444-453.
49. Schetelig J, Bornhauser M, Schmid C et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: A report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26:5183-5191.
50. Mengis C, Aebi S, Tobler A et al. Assessmentofdifferences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 2003;21:3933-3939.
51. Balducci L, Cohen HJ, Engstrom PF et al. Senior adult oncology clinical practice guidelines in oncology. J Natl ComprCanc Netw 2005;3:572-590.
52. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-2919.
53. Giles FJ, Borthakur G, Ravandi F et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007;136:624-627.
54. Extermann M, Overcash J, Lyman GH et al. Comorbidity and functional status are independent in older cancer patients. J Clin On col 1998;16:1582-1587.
55. Katz S. Assessing self-maintenance: Activities of daily living, mobility, and instrumental activities of daily living. J Am GeriatrSoc 1983;31:721-727.
56. Lawton MP, Brody EM. Assessment ofolder people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
57. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology study. J Clin Oncol 2002;20:494-502.
58. Guralnik JM, Simonsick EM, Ferrucci L et al. A short physical performance battery assessing lower extremity function: Association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85-M94.
59. Studenski S, Perera S, Wallace D et al. Physical performance measures in the clinical setting. J Am Geriatr Soc 2003;51:314-322.
60. Flood KL, Carroll MB, Le CV et al. Geriatric syndromes in elderly patients admitted to an oncology-acute care for elders unit. J Clin Oncol 2006;24:2298 -2303.
61. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005;104:788 -793.
62. Landefeld CS, Palmer RM, Kresevic DM et al. Arandomized trial of care in a hospital medical unit especially designed to improve the functional outcomes of acutely ill older patients. N Engl J Med 1995;332:1338-1344.
63. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007;32:169-175.
64. Corcoran ME. Polypharmacy in the older patient with cancer. Cancer Control 1997;4:419-428.
65. Yates J, Glidewell O, Wiernik P et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 1982;60:454-462.
66. Deschler B, de Witte T, Mertelsmann R et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches. Haematologica 2006;91:1513-1522.
67. Sekeres MA, Stone RM, Zahrieh D et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004;18:809-816.
68. Faderl S, Verstovsek S, Cortes J et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108:45-51.
69. Giles F, Rizzieri D, Karp J et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007;25:25-31.
70. Faderl S, Ravandi F, Huang X et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638 -1645.
71. Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006;106:1794-1803.
72. Nand S, Godwin J, Smith S et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: Results from a pilot trial. Leuk Lymphoma 2008;49:2141-2147.